Cerus Corporation CERS
2.07 USD +0.05 (+2.48%)
At closeNov 9, 2026, 6:59 PM EST
2.07 0.00 0.00%
After hours · Nov 9, 6:59 PM ET
1.91 Day range 2.10
1.47 52-week range 3.47
- YTD
- +0.49%
- 1 year
- +21.05%
News
benzinga.com Adeia Posts Downbeat Q3 Earnings, Joins Bioventus, Apple And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. futures mixed as Adeia plunges 23% after missing Q3 estimates and cutting FY26 guidance; Bioventus, Emergent and others also fall premarket.
fool.com Cerus: 3 Key Takeaways for Long-Term Investors A shift to higher-margin kit distribution and a successful red blood cell trial position Cerus for path to GAAP profitability.
benzinga.com Why Aehr Test Systems Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket Aehr surged 15% after strong Q1 results and raised FY27 guidance; Mercer, HUB Cyber and Parabolic led gainers, while VCIG and Jaguar fell.
seekingalpha.com Cerus Corporation (CERS) Q3 2026 Earnings Call Transcript Cerus Corporation ( CERS ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants Timothy Lee - Head of Investor Relation Vivek Jayaraman - CEO, President & Director Kevin Green - VP…
marketbeat.com Cerus Q3 Earnings Call Highlights Cerus NASDAQ: CERS reported third-quarter product revenue growth of 10% year over year and reaffirmed its 2026 revenue outlook, while also announcing positive top-line results from its Phase III…
benzinga.com Cerus Q3 2026 Earnings Call Transcript Cerus (NASDAQ:CERS) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
reuters.com Cerus' blood-safety system meets main goal in late-stage trial Cerus' blood-safety system meets main goal in late-stage trial
benzinga.com Cerus Affirms FY2026 Sales Guidance of $229.000M-$231.000M vs $248.850M Est Cerus (NASDAQ:CERS) affirms FY2026 sales outlook from $229.000 million-$231.000 million to $229.000 million-$231.000 million vs $248.850 million estimate.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 16.2% to $4.67 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million. Cerus…
businesswire.com Cerus Corporation Announces Third Quarter 2026 Financial Results CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the third quarter ended September 30, 2026, and provided a business update. "Our solid…
businesswire.com Cerus Corporation Announces Positive Topline Results from Phase 3 RedeS Trial of the INTERCEPT Blood System for Red Blood Cells CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced positive topline results from the Phase 3 RedeS (NCT03037164) trial. “Over the past decade, pathogen reduction…
benzinga.com Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures rise, Nasdaq 100 up 300 points. Apple Inc shares fall 7.4% despite beating analyst estimates for Q3. Other stocks also dip in pre-market.- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's after-market session. The market value of their outstanding shares is at $297.1 million. uniQure…
benzinga.com Cerus Q2 EPS $(0.01), Inline, Sales $57.441M Miss $60.933M Estimate Cerus (NASDAQ:CERS) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is a 66.67 percent increase over losses of $(0.03) per share from the same period…
benzinga.com Cerus Raises FY2026 Sales Guidance from $227.000M-$231.000M to $229.000M-$231.000M vs $245.200M Est Cerus (NASDAQ:CERS) raises FY2026 sales outlook from $227.000 million-$231.000 million to $229.000 million-$231.000 million vs $245.200 million estimate.
benzinga.com Cerus Announces William Greenman Ceases As President And CEO, Becomes Executive Chairman Effective July 1, 2026 https://www.sec.gov/ix?doc=/Archives/edgar/data/0001020214/000102021426000015/cers-20260706.htm
benzinga.com Cathie Wood Sells Robinhood Stock, Doubles Down On This George Soros-Backed AI Stock On Wednesday, June 10, 2026, Ark Invest sold $7.8M in Robinhood shares Wednesday while adding 141,502 shares of Kodiak AI
benzinga.com Top 2 Health Care Stocks That May Plunge This Month Health care stocks flashing warning for momentum investors. RSI measures stock strength, overbought when above 70. AVNS +127% past 6 months, AGL +212% past month.
benzinga.com Top 3 Health Care Stocks That May Collapse This Month Stocks AVNS, APLS, and CERS in healthcare sector flashing warning to momentum-sensitive investors. High RSI values & price action indicate overbought conditions. AVNS at 90. APLS at 86. CERS at 86.…
benzinga.com This Caterpillar Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday Top analysts upgraded APD, CAT, CERS, PPC, and HSY stocks with increased price targets. Check out analysts' views on these stocks before buying.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com Cerus Q1 2026 Earnings Call Transcript
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com Cerus Raises FY2026 Sales Guidance from $224.000M-$228.000M to $227.000M-$231.000M vs $242.400M Est Cerus (NASDAQ:CERS) raises FY2026 sales outlook from $224.000 million-$228.000 million to $227.000 million-$231.000 million vs $242.400 million estimate.
- benzinga.com Cerus Q1 EPS $(0.01) Beats $(0.04) Estimate, Sales $53.661M Beat $53.167M Estimate Cerus (NASDAQ:CERS) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.04) by 75 percent. This is a 75 percent increase over losses of $(0.04) per share…
benzinga.com Earnings Scheduled For April 30, 2026 - benzinga.com Cerus Signs Four-Year Supply Agreement With Établissement Français Du Sang For INTERCEPT Blood And Platelet Pathogen Inactivation System The EFS distributes approximately 330,000 units of platelets annually across 13 regional centers in continental France and overseas territories. The INTERCEPT Blood System for platelets has been used…
benzinga.com MongoDB, Surgery Partners, Harrow And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session MDB stock fell 27.2% in pre-market trading after reporting Q4 earnings of $1.65 per share, revenue of $695.07M, and Q1 guidance below estimates.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com Cerus Q4 Earnings Assessment - benzinga.com Cerus Affirms FY2026 Sales Guidance of $224.000M-$228.000M Cerus (NASDAQ:CERS) affirms FY2026 sales outlook from $224.000 million-$228.000 million to $224.000 million-$228.000 million.
- benzinga.com Cerus Q4 EPS $(0.01), Inline, Sales $57.751M Miss $58.075M Estimate Cerus (NASDAQ:CERS) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of…
- benzinga.com Earnings Scheduled For March 2, 2026
benzinga.com Earnings Preview For Cerus 
benzinga.com TG Therapeutics, Clover Health Investments, Nutrien And Other Big Stocks Moving Higher On Wednesday - benzinga.com Reported Earlier, Cerus Reports Preliminary 2025 Product Revenue Of $206.1M, Up 14% YoY; Guides 2026 Product Revenue Of $224M–$228M On 9%–11% Growth And IFC Revenue Of $20M–$22M Preliminary Full-Year 2025 Product Revenue of $206.1 MillionFull-Year 2026 Product Revenue Expected to be $224 Million to $228 Million, Reflecting 9%-11% Growth, Year-Over-Year
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com Earnings Scheduled For August 5, 2025
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Earnings Scheduled For May 1, 2025
- benzinga.com Earnings Scheduled For February 20, 2025
- benzinga.com S&P 5000 Edges Higher; US Crude Oil Inventories Fall
- benzinga.com Crude Oil Edges Higher; US Retail Sales Top Expectations
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com CSX Posts Weak Earnings, Joins Lucid Group, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session 
benzinga.com Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 47%; Here Are 20 Stocks Moving Premarket - benzinga.com ZoomInfo Reports Weak Results, Joins Chegg And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
benzinga.com Perion Network Cuts Sales Outlook, Joins Range Resources And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures were mixed this morning, with the Dow futures falling by around 10 points on Monday.- benzinga.com Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.
- benzinga.com Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday.